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SUMMARY
Mitochondria are essential in long axons to provide
metabolic support and sustain neuron integrity. A
healthy mitochondrial pool is maintained by biogen-
esis, transport, mitophagy, fission, and fusion, but
how these events are regulated in axons is not well
defined. Here, we show that the Drosophila gluta-
thione S-transferase (GST) Gfzf prevents mitochon-
drial hyperfusion in axons. Gfzf loss altered redox
balance between glutathione (GSH) and oxidized
glutathione (GSSG) and initiated mitochondrial fusion
through the coordinated action of Mfn and Opa1.
Gfzf functioned epistatically with the thioredoxin
peroxidase Jafrac1 and the thioredoxin reductase 1
TrxR-1 to regulate mitochondrial dynamics. Altering
GSH:GSSG ratios in mouse primary neurons in vitro
also induced hyperfusion. Mitochondrial changes
caused deficits in trafficking, the metabolome, and
neuronal physiology. Changes in GSH and oxidative
state are associatedwith neurodegenerativediseases
like Alzheimer’s.Our demonstration thatGSTs are key
in vivo regulators of axonal mitochondrial length and
number provides a potential mechanistic link.
INTRODUCTION
Most neurons are generated during embryogenesis and are sub-
sequently maintained throughout the entire life of an organism.
Mitochondria are integral to sustaining neuronal health, and the
long polarized processes of neurons pose a unique challenge
for adequate mitochondrial positioning and maintenance.
Cellular homeostasis and adequate ATP production is thought
to be achieved in axons through regulation of several essential
mitochondrial processes, including mitochondrial fusion, fission,
biogenesis, degradation, and transport (Harbauer, 2017). The
major pathways responsible for regulating these have been
increasingly well described over the past decade and are highly
conserved from humans to Drosophila (Hewitt and Whitworth,
2017; Vanhauwaert and Verstreken, 2015), but whether they uni-
formly regulate mitochondrial biology similarly in all neuronal
compartments remains an open question.
Rapid and dynamic changes in mitochondrial length occur in
response to the ever-changing environment of the cell (van der
Bliek et al., 2013). Conditions that increase mitochondrial ATP
consumption lead to enhanced fusion, allowing for the mixing
of mtDNA and proteins, whereas metabolic signals that grossly
uncouple the mitochondria may result in fusion inhibition and
occur as a prerequisite to mitophagy and/or neurodegeneration
(van der Bliek et al., 2013). Increased mitochondrial length can
be classically achieved through increased function of the mito-
chondrial fusion proteins mitofusin (MFN) and optic atrophy 1
(OPA1) or decreased activity of the mitochondrial fission factors
dynamin-related protein 1 (DRP1) and fission mitochondrial 1
(FIS1) (van der Bliek et al., 2013). The precise cellular processes
that control the expression and function of these molecules for
the dynamic regulation of mitochondria in long axon stretches
are not well understood under physiological conditions or in
complex diseases. Few key upstream modulating factors of
the fission-fusion machinery have been identified (Anding
et al., 2018; van der Bliek et al., 2013; Burman et al., 2017;
Farmer et al., 2017; Otera and Mihara, 2011; Otera et al., 2013).
Oxidation and reduction (redox) reactions of the glutathione
(GSH) pathway take place in all cells and are essential for vital
metabolic processes, including the production of ATP. Gluta-
thione S-transferases (GSTs), reductases (GR), and peroxidases
(GPx) control redox homeostasis and tightly balance the ratio of
the antioxidant GSH and the toxic species oxidized glutathione
(GSSG) (Aquilano et al., 2014). Mitochondria can be affected
by GSH redox changes that manifest in neurological diseases
and stress response conditions by several mechanisms. First,
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mitochondria cannot produce GSH themselves, so they rely on
its import from the cytoplasm for the adequate detoxification
of reactive oxygen species (ROS) (Marı´ et al., 2009; Ribas
et al., 2014). Second, GSSG accumulation can cause wide-
spread oxidation of proteins and lipids, including essential mito-
chondrial proteins of the electron transport chain (Marı´ et al.,
2009; Ribas et al., 2014). While large shifts in intracellular redox
are detrimental to cells, small shifts in the GSH:GSSG ratio have
been reported to induce mitochondrial-associated changes that
are not associated with toxicity in vitro (Shutt et al., 2012).
In this study, we developed a high-throughput method to iden-
tify new molecules required for axonal mitochondrial mainte-
nance in vivo. We discovered that a novel GST, Gfzf, homolo-
gous to GSTT1 in humans, regulates mitochondrial length in
axons and functions by altering redox balance. Ablation of gfzf
was found to cause the oligomerization of the outer mitochon-
drial membrane fusion factor Marf, a fly homolog of MFN, to
initiate the fusion process and induce a complete fusion of the in-
ner membrane through a secondary OPA1-mediated response.
We show that mitochondrial fusion events also require the coor-
dinated action of the specific GPx Jafrac1 and can be amelio-
rated by the expression of the GR TrxR-1. Loss of this GST
caused significant functional changes within the neuron,
including mitochondrial trafficking and electrophysiology. GSTs
can therefore be classified as new essential upstream regulators
of redox-mediated mitochondrial fusion.
RESULTS
A High-Throughput In Vivo Genetic Screen for Modifiers
of Axonal Mitochondria
Mitochondrial maintenance processes present in non-polarized
cells may occur in the axonal compartment of neurons
(Amiri and Hollenbeck, 2008; Ashrafi and Schwarz, 2015; Ashrafi
et al., 2014; Cartoni et al., 2016; Harbauer, 2017; Lee et al., 2018;
Misgeld and Schwarz, 2017; Schwarz, 2013), but the similarities
or differences remain poorly defined. We devised an in vivo for-
ward genetic screen to identify new factors controlling mito-
chondrial dynamics in axons with single axon and mitochondrial
resolution using Drosophila (Figure 1A). We used the MARCM
system to visualize a subset of glutamatergic neurons in the adult
Drosophila wing (Neukomm et al., 2014) and simultaneously
labeled mitochondria (Figure 1B). Flies were fed the chemical
mutagen ethylmethane sulfonate (EMS) and crossed to generate
progeny containing MARCM clones in the F1 generation (Neu-
komm et al., 2017). These animals were screened for changes
in mitochondrial number, size, and position. This approach
allowed us to discover both lethal and nonlethal mutants that
regulate mitochondrial in adult post-mitotic neurons in vivo.
To begin characterizing this system, we assayed the effects of
loss-of-function manipulations of knownmolecules that regulate
mitochondrial biology at 7 days post-eclosion (p.e.) (Figure 1C).
Mitochondria in control neurons were distributed throughout the
cell body and the axon and were stereotyped in size and density
per unit axon area (Figure 1Ci). Induction of neuronal clones with
a null mutation in the mitochondrial transport gene Milton re-
sulted in the failure of mitochondria to enter the axonal compart-
ment (Figure 1Cii), in agreement with Vagnoni et al. (2016). Muta-
tions in mitochondrial fission gene Drp1 caused fusion of
mitochondria in the axon and a hyperfusion phenotype in the
cell body (Figure 1Ciii; Figure S1). Mutants lacking the fusion fac-
tor Marf exhibited a significant shortening of mitochondria within
the axon and a diffuse appearance in the soma (Figure 1Civ).
Given the high efficiency and resolution of this system for exam-
ining mitochondrial phenotypes in axons in an in vivo setting
and the potential to identify new regulators of mitochondrial
Figure 1. A Forward Genetic Screen to
Analyze Mitochondria Dynamics in Axons
(A) The mitochondria screen was designed
such that male flies in the F1 generation were
collected for wing dissection that was rapidly
visualized by fluorescent microscopy at 7 days
p.e.
(B) Random mutations in the genome were
induced by the chemical mutagen EMS, and the
effect visualized in homozygous clones using the
MARCM approach (mitochondria, green; neuronal
clones, red).
(C) The mitochondrial screen was verified using
known mitochondrial modifying mutants of Milton
[EY4443], Drp11, and Marf [J], such that modifi-
cations in mitochondrial transport and length can
be clearly observed at 7 days p.e. compared to
controls in both the axonal and/or cell body
cellular compartments, as depicted in the sche-
matic. Arrows indicate significantly changed
mitochondrial phenotypes in axons.
Scale bars, 10 mm.
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physiology, we screened through 8,000 mutagenized chromo-
somes on the left arm of the 3rd chromosome (representing
20% of the Drosophila genome). We discovered one lethal
mutant, line #541, where mitochondria were significantly longer
in axons compared to non-mutagenized controls, which we
functionally characterize below.
Loss of Gfzf Results in Increased Mitochondrial Length
in Axons
A combination of whole-genome sequencing and deficiency
mapping was used to identify a premature stop mutation in
GST-containing FLYWCH zinc-finger protein (gfzf), a GST gene,
that caused the long mitochondrial phenotype. Outcrossed flies
that retained the phenotype were always associated with
lethality. We found three overlapping deficiencies that failed to
complement #541 in thegenomic region ofgfzfmutation revealed
by the sequencing. Based on this observation and rescue exper-
iments (below) we refer to mutant #541 as gfzf/.
Figure 2. Mutations in a Novel Mitochon-
drial-Regulating Gene, gfzf, Cause an In-
crease in Mitochondrial Length
(A) Mutations in the gene gfzf caused an age-
dependent increase in mitochondrial length and a
reduction inmitochondrial number, as visualized in
the proximal region of the axons (mitochondria,
green; neuronal clones, red).
(B) The increase in mitochondrial length compared
to control was not significantly different at 2 days
p.e. and was increased 3- to 4-fold at both 7 and
28 days p.e.
(C) Mitochondrial number was found to be
marginally reduced at 2 days p.e. and greatly
reduced in gfzfmutant axons at both 7 and 28 days
p.e.
(D) Analyzing the distribution of mitochondria
lengths in the proximal axons at 7 days revealed
that there was a significant shift in gfzf/ clones to
lengths of R2.61 mm, with no control mitochon-
drial reaching these lengths.
Data were analyzed by 2-way ANOVA and signifi-
cant differences annotated as *p < 0.05, **p < 0.01,
and ***p < 0.001 between genotypes and xp < 0.05,
xxp < 0.01, and xxxp < 0.001 across age. Data in
graphs are expressed as mean ± SEM and NR 10
wings for each group. Scale bar, 10 mm.
Increased mitochondrial length in
gfzf/ mutants was found to be age
dependent (Figure 2). While only a mini-
mal phenotypic difference was observed
at 2 days p.e., excessively longmitochon-
dria were observed at both 7 and 28 days
(Figure 2A). Mitochondrial morphology
was also altered in the neuronal cell
bodies of gfzf/ mutant clones at later
time points (Figure 2A). Quantification of
mitochondrial length in axons revealed
that at 7 and 28 days, mitochondria
were on average 3–4 times longer than
age-matched controls (Figure 2B), and the total number of mito-
chondria significantly decreased (Figure 2C). For instance, by
28 days p.e., one single long mitochondrion was observed in a
60 mm length of mutant axon, whereas control neurons con-
tained 5 shorter mitochondria (Figure 2C). Analysis of the fre-
quency distribution of mitochondrial length in gfzf/ mutant
axons revealed a shift in length from a typical control range of
0.1–2.61 mm to a much broader range of 0.41 to >5 mm
(Figure 2D).
In the experiments described above, mitochondrial lengths
were analyzed in a defined region of the proximal wing (Fig-
ure 1A). However, given the substantial length of these glutama-
tergic neurons, we wished to determine whether the alterations
in mitochondrial length observed in gfzf#541 mutants were pre-
sent throughout the axon, and this was indeed the case (Figures
S2A and S2B). A frequency distribution shift of mitochondrial
length also manifested as animals aged (Figures S2C–S2E).
Therefore, gfzf/ mutants affected mitochondrial length in
54 Neuron 103, 52–65, July 3, 2019
Figure 3. Increased Mitochondrial Length in gfzf Mutants Is Caused by GST Activity Altering Electrophysiological Properties
(A) Increasedmitochondrial length and reducedmitochondrial number were rescued to control levels by re-expression of the full-length cDNA of gfzf, as observed
at 7 days p.e.
(B) The increase in mitochondrial length compared to control was significantly rescued to control levels under the following conditions: expression of full-length
gfzf cDNA, cDNA containing just the GST domain (DN), a genomic BAC duplication construct for gfzf expression, and cDNA for another GST-domain-containing
gene, dGSTO1, and hGSTT1.
(C) Decreased mitochondrial number also rescued to control levels under the same paradigms that were found to rescue mitochondrial length increases.
(D–G) The function of the long mitochondria in gfzf/ clones was also assessed with in vivo live-cell imaging using mitochondrial-specific reporters for calcium
(GCaMP5), age andmaturation (mitoTimer), glutathione redox (Grx1-roGFP2), and H2O2 redox glutathione redox (roGFP2-Opr1). Mitochondria residing in mutant
clones showed no significant functional changes in either calcium levels (D) or age (E), as measured by fluorescence intensity, at 7 days p.e. compared to control
mitochondria. Reporters showed that GSSG levels were increased in mitochondria (F), yet H2O2 levels remained unchanged (G).
(H) Electroretinogram (ERG) recordings were conducted in aged flies at 28 days p.e. using a GFP flipout clone system and the annotated parameters quantified.
ERG was measured at a range of LED intensities.
(I and J) The on-transient peak did not differ betweenWT and gfzf/mutant backgrounds (I); however, significant changes in the off-transient peak were seen (J).
(legend continued on next page)
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axons independent of their location relative to the soma, and the
effect increases with age. The total percentage axonal area
occupied by mitochondria in the distal wing was further quanti-
fied within the axon and cell body compartments and not signif-
icantly changed (Figures S2F and S2G). This indicated that the
mitochondrial phenotype is likely a fission-fusion deficit that
does not affect biogenesis or degradation pathways.
To confirm that the stop mutation in gfzf/ was indeed
responsible for the alterations in mitochondrial size, we ex-
pressed a full-length wild-type gfzf cDNA in gfzf#541 mutant
clones. Upstream activating sequence (UAS)-mediated expres-
sion of gfzf was sufficient to rescue long mitochondrial
phenotypes observed in the axons and cell bodies at 7 days
p.e. (Figure 3A). Expression of 5xUAS-gfzf significantly reduced
mitochondrial length compared to baseline, equivalent to those
observed in controls (Figures 3B and 3C). A genomic bacterial
artificial chromosome (BAC) clone also fully rescued the mito-
chondrial phenotype in gfzf#541 mutants (Venken et al., 2009),
(Figures 3B and 3C). Autonomous expression of gfzfDN, which
still harbors the GST domain (but lacks the zinc finger [ZNF] do-
mains), was also sufficient to rescue the mitochondrial pheno-
type in gfzf mutants. These findings argue that the GST domain
is the key regulatory domain in Gfzf necessary to modulate mito-
chondrial length in axons.
A range of other mutants of gfzf have been generated (Pro-
vost et al., 2006), outlined in (Figure S3A), but we found that
the nature of these mutations was less severe than gfzf#541.
gfzf#541 was the only allele that failed to complement the
lethality of a deficiency lacking gfzf, or a transposon inserted
in gfzf Mi(MIC)gfzfMI08697 (Figure S3B). We therefore propose
that gfzf#541 is a null allele and will also refer to gfzf#541 as
gfzf/. gfzfCZ811 also failed to complement most other alleles,
including gfzf/ and the Mi(MIC)gfzfMI08697 line, and showed
increased mitochondrial length and decreased mitochondrial
number (Figures S3C–S3E). No clones were observed
gfzfCL1027, suggesting this chromosome arm may harbor an
additional cell lethal mutation. This independently derived allele
further confirms that loss of Gfzf causes increased mitochon-
drial length. Rescue experiments indicate that embryonic
lethality caused by Gfzf loss was likely not the result of
neuronal-specific deficits, decreased GST activity, or mito-
chondrial fusion perturbations (Figure S3F). Therefore, Gfzf
seems to have a dual role: an essential role in fly development
in other tissues that does not depend on GST activity and a
role to maintain mitochondrial length in adult neurons in which
GST is both necessary and sufficient. The GST domain of Gfzf
has a 30% identity and 48% homology with the GST domain
of human GSTT1 (Figure S3G). Cas9 and guide RNA (gRNA)-
mediated targeting of the mammalian GST homolog GSTT1
was also sufficient to increase mitochondrial length in cultured
neurons in vitro (Figure S4), arguing for strong conservation of
GST-mediated regulation of mitochondrial size.
GST Regulates Mitochondrial Length and Neuronal
Function
Mitochondrial phenotypes were first rescued by expression of
Gfzf in gfzf/ clones confirming the causative gene (Figure 3A)
before investigating the interaction with other GSTs. There are
multiple GSTs in the Drosophila genome, all of which can likely
regulate GSH:GSSG ratios. To determine whether the ability of
the GST domain of Gfzf to regulate mitochondrial length was
specific, we tested whether other cytoplasmic localized GSTs
could compensate for Gfzf or directly regulate mitochondrial
length in axons (Figures 3B and 3C). We found that the expres-
sion of dGstO1 could reducemitochondrial length in gfzf/ neu-
rons (Figure 3B). This suggests that GST-domain-containing
proteins in Drosophila have the general ability to regulate mito-
chondria and may function synergistically to determine axonal
mitochondrial length. GST-domain-containing proteins are high-
ly conserved between the fruit fly and humans. We further found
that mitochondrial length in gfzf/ clones was rescued by
expression of hGSTT1, (Figure 3B), but not hGSTT2, hGSTO1,
hGSTO2, and hGSTM1 (Table S1), arguing that human GSTT1
may be the most conserved GST-containing protein for main-
taining mitochondria dynamics in neurons. Rescue of mitochon-
drial length was always accompanied with a rescue in number
per unit of axon length (Figure 3C), supporting a causal link be-
tween these phenotypes.
Genetic manipulations that lead to dramatic changes in mito-
chondrial morphology are also tightly associated with perturba-
tion of mitochondrial physiology and age-dependent neurode-
generation. We used in vivo live-cell imaging to assess
mitochondrial Ca2+ levels, mitochondrial age and redox potential
specific to GSSG and H2O2, in gfzfmutant clones, using 5xUAS-
mito-GCaMP5, 5xUAS-mitoTimer, 5xUAS-mito-Grx1-roGFP2
and 5xUAS-mito-roGFP2-Orp1 respectively (Figures 3D–3G).
We detected no significant differences in the fluorescence inten-
sity of mitochondrial localized GCaMP5 (Figure 3D) and mito-
Timer (Figure 3E). These data support the notion that mitochon-
dria in gfzf/ mutant axons remain broadly functional. There
was a significant increase in the fluorescence intensity depicting
GSSG within the mitochondria from 7 days, which was not
detectable in controls (Figure 3F). The fluorescence signal de-
noting H2O2 levels remained unchanged (Figure 3G). Electroret-
inogram (ERG) recordings in aged flies further indicated that
these dynamic mitochondrial changes were associated with
neuronal response phenotypes (Figures 3H–3M). Amplitude of
the off-transient was reduced, the time to reach half-maximal
corneal depolarization was delayed, and the time to fully repo-
larize was shortened in gfzf/ backgrounds relative to wild
(K–M) Corneal depolarization was not significantly changed (K); however, the half-time to corneal depolarization (L) and time to repolarization (M) were affected by
gfzf ablation. A kinesin motor transport mutant, Kif19A/, was used as a positive control throughout.
Data for rescue experiments were analyzed by 2-way ANOVA and significant differences annotated as ***p < 0.001 between genotypes of the same treatment and
xp < 0.05 between baseline controls. Data for live-cell imaging experiments to determine mitochondrial function were analyzed by t test or 2-way ANOVA and
significant differences annotated as *p < 0.05 between genotypes. For ERG, significant differences betweenKif19A/ and control were annotated as ***p < 0.001
and gfzf/ and control as #p < 0.05, ##p < 0.01, and ###p < 0.001. Data in graphs are expressed asmean ± SEMandNR 10wings for each group or n = 6 flies (I–M)
for each group. For roGFP experiments, 1–7mitochondria were averaged per wing (depending on genotype). Scale bars represent 10 mm (top) and 4 mm (bottom).
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type (WT). Changes were rescued by a BAC clone or pan-
neuronal knockdown of Marf, suggesting that physiological re-
sponses were directly related to the GSH pathway and mito-
chondrial hyperfusion (Figures S5A–S5C). gfzf/ mutant axons
remain intact in vivo, and baseline Ca2+ levels were not signifi-
cantly different from control, yet a significant decrease in mito-
chondrial transport was observed (Figures S5D–S5G). This indi-
cates that large mitochondria had significantly higher GSSG
content, which may impact bioenergetics, transport, and
neuronal function.
Cytoplasmic Gfzf Regulates Mitochondria in Multiple
Neuronal Subtypes without Altering the Distribution of
Other Axonal Organelles
We generated a transgenic stock containing 5xUAS-gfzf::GFP
and drove its expression using the pan-neuronal synapsin1-
Gal4 driver. Gfzf::GFP was observed throughout the neuron (Fig-
ure S6A). The localization of this molecule in cultured Drosophila
S2 cells is also cytoplasmic (Dai et al., 2004). Regulation of mito-
chondrial size by Gfzf was also observed in other neuronal sub-
types (Figures S6B–S6E). Interestingly, morphological changes
in mitochondria were not observed at synaptic terminals or in
glial clones (Figures S7A and S7B), suggesting that synaptic
and glial mitochondrial size may be regulated by different mech-
anisms or other GSTs. Finally, we examined other organelles (ly-
sosomes, endosomes, and peroxisomes) and observed no dif-
ferences in distribution, number, and size of these vesicles
between genotypes (Figures S7C–S7E). Together these data
indicate that the Gfzf selectively regulates mitochondria in a
pan-neuronal fashion and contributes to shaping the mitochon-
drial network in the axonal and cell body compartments.
Increased Mitochondrial Length in gfzf Mutants Is
Caused by Excessive Fusion
To explore the mechanism by which long mitochondria are
generated in gfzfmutant clones, we examined the epistatic rela-
tionship between Gfzf and known fission and fusion factors. We
found that increased expression of Drp1, Marf, or Pink1 and
RNAi-mediated knockdown of Marf or Opa1 in adult neurons
in vivo were sufficient to rescue the long mitochondrial pheno-
type of gfzf/ mutants (Figures 4A and 4B). Knockdown of the
mitochondrial fusion factors Opa1 and Marf caused a complete
rescue of the long mitochondrial phenotype, which was also
observed in double mutants of gfzf/, Opa1+/ (Figure 4B). In
each case, factors that increased mitochondrial length resulted
in a decrease in mitochondrial number (Figure 4C). Interestingly,
we found that promoting fusion by expression of Marf caused a
biphasic shift in mitochondrial length and number (Figures 4D
and 4E) and ultimately age-dependent neurodegeneration
(Figure 4F). We simultaneously knocked down Marf in neurons
overexpressing Gfzf, and no additive effect was observed,
providing further epistatic evidence that Gfzf and Marf act in
the same genetic pathway (Table S2). These observations indi-
cate the increased mitochondrial length observed in gfzf/
mutant clones can be reversed by altering factors in the classical
fission-fusion pathway and suggest that increasedmitochondrial
length in gfzf null clones is caused by hyperfusion of mitochon-
dria. The GST activity of Gfzf is therefore a novel potential
upstreammodulator of inner and outer mitochondrial membrane
fusion.
Glutathione Redox Changes Regulate Mitochondrial
Dynamics in Cultured Mouse Primary Neurons
GSTs bind GSH to oxidized molecules and lipids for the purpose
of cellular detoxification (Marı´ et al., 2009; Ribas et al., 2014),
producing GSSG as a byproduct. We speculated that GSTs
might modulate the capacity of Marf to drive mitochondrial
fusion through a shift in the GSH:GSSG ratio. To test this possi-
bility, we used two small-molecule treatments to change the
redox state in cultured mouse primary cortical neurons: L-bu-
thionine-sulfoximine (BSO) to block GSH synthesis (Dai et al.,
2004) and diamide (Dia) to induce the rapid conversion of GSH
toGSSG.We found that 48 h of BSO treatment or 1 h of Dia treat-
ment resulted in clear morphological changes of mitochondria in
cortical neuron projections (Figures 5A and 5B). Under these
conditions, there was no evidence of cell death (Table S3). Mito-
chondria in neurites were significantly longer following BSO or
Dia treatments compared to vehicle (Figure 5C), and the number
of mitochondria was reduced compared to vehicle treatment
(Figure 5D), phenocopying genetic in vivo data. These results
show that reducing GSH:GSSG ratios initiates increases in mito-
chondrial length in mammalian neuronal projections.
To explore how increased GSSGmight modulate known com-
ponents of themitochondrial fusionmachinery, we examinedmi-
tofusin 2 (MFN2) localization in primary neuron cultures. Treat-
ment with BSO or Dia resulted in MFN2-positive puncta that
were larger in size and fewer in number compared to vehicle con-
ditions (Figure 5E). This suggests that heightened GSSG levels
might act by increasing oligomerization of MFN2 to promote
fusion, as described previously (Shutt et al., 2012). Biochemical
analysis further showed that the redox state had no obvious ef-
fect on fission-fusion factors other than MFN2 (Figures 5F and
5G). These experiments support the notion that GST-dependent
modulation of glutathione redox balance is an evolutionarily
conserved mechanism by which MFN2 oligomerization can be
altered to modulate mitochondrial dynamics in axons.
Mild Changes in GSH Redox Is Nondisruptive and
Selective to Mitochondrial Fusion
The dramatic changes in mitochondrial size we observed by
manipulating GSTs in vivo or the GSH:GSSG balance in vitro
might be predicted to have significant effects on mitochondrial
metabolism or physiology. Similar to our in vivo findings, phar-
macological treatments with BSO and Dia did not cause
increased ROS or loss of mitochondrial membrane potential,
visualized using live imaging with MitoSOX and tetramethylrhod-
amine ethyl ester (TMRE), respectively, compared to the
carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP)-
treated positive control (Figures 6A–6C). However, levels of
GSH, measured by ThiolTracker, were markedly reduced (Fig-
ures 6A and 6D). Biochemical analysis using cell lysates also
showed that BSO and Dia treatment led to a reduction of GSH
and, as expected, GSSG was significantly increased by Dia
treatment, (Figure 6E). Normal homeostatic mechanisms would
be predicted to allow for the conversion of GSSG back to GSH
via NADPH. While NADP remained unchanged by BSO or Dia
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treatments, NADPH levels were significantly reduced (Figure 6F).
Decreased NADPH levels were accompanied by a drop in the
ATP:ADP ratio (Figure 6G), a relationship previously reported
by monochlorobimane treatment (Vesce et al., 2005). BSO or
Dia treatment did not have an effect on total mtDNA copy num-
ber, (Figure 6H), indicating that GSSG-regulated events did not
enhance or decrease the total mitochondrial network size.
We next investigated the metabolic profile of neurons with al-
terations in GSH:GSSG ratios. A large number of metabolites
were differentially altered following BSO and Dia treatment,
and the GSH pathway was the most dysregulated by the
GSH:GSSG ratio change, as expected (Figure 6I). BSO treat-
ment also caused a significant decrease in glycine, cysteine-
glycine, oxoproline, and glutamine (Figure 6J), and Dia treatment
caused a similar change (Figure 6K). Other changes are anno-
tated in Tables S4 and S5. Glutamate levels were drug depen-
dent. Metabolite changes were mapped onto the mouse KEGG
GSHpathway (Figure 6L), highlighting how changingGSH:GSSG
Figure 4. Increased Length in gfzf–/– Mutant Clones Is the Result of Excessive Mitochondrial Fusion
(A) Targeted epistasis experiments show howoverexpressing and knocking down knownmitochondrial regulating genes (fission, fusion andmitophagy) in control
and gfzf/ mutant clones can alter mitochondrial distribution and size in the axon and cell body compartments.
(B) Increased mitochondrial length phenotypes, observed at 7 days p.e., in gfzf/ mutant clones were rescued by OK371-Gal4-driven expression of 5xUAS-
Drp1, 5xUAS-Pink1, 5xUAS-Marf RNAi, and 5xUAS-Opa1RNA and in heterozygous Opa1mutants. Average mitochondrial length in control clones were increased
above controls levels following expression of 5xUAS-Marf in gfzf/ axons at 7 days.
(C) Decreased numbers of mitochondria in the axon stretches of gfzf/ mutant clones were rescued by expression of 5xUAS-Drp1, 5xUAS-Marf RNAi, and
5xUAS-Opa1RNAi and in heterozygous Opa1 mutants. 5xUAS-Marf expression caused a reduction of mitochondrial number in control clones.
(D) A biphasic shift in mitochondrial length was observed following expression 5xUAS-Marf over time, causing a significant increase in mitochondrial length at
1 day p.e. in control clones, whereas longmitochondrial phenotypes seen in gfzf/mutant clones remain unchanged compared to control levels (dashed line). At
5 and 10 days p.e., mitochondrial length was decreased, regardless of genotype.
(E) Expression of UAS-Marf also causes a significant reduction in mitochondrial number at 1, 5, and 10 days p.e. compared to controls (dashed line), regardless of
genotype.
(F) Expression of 5xUAS-Marf caused progressive neurodegeneration, and significantly fewer number axons were quantified at 10 and 14 days p.e.
Data for rescue experiments were analyzed by 2-way ANOVA and significant differences annotated as *p < 0.05 and **p < 0.01 between genotypes following the
same treatment and xp < 0.05 and xxp < 0.01 between experimental groups and their respective baseline controls. Data in graphs are expressed as mean ± SEM
and NR 10 wings for each group. Scale bar, 10 mm.
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Figure 5. Pharmacologically Altering Glutathione Homeostasis in Mammalian Neurons In Vitro Results in Excessive Mitochondrial Fusion
(A) 3-week-old primary cortical neurons were treated with either diamide (Dia) at a concentration of 100 mm for 2 h or L-buthionine-sulfoximine (BSO) at a
concentration of 600 mm for 48 h. Following fixation, neurons and mitochondria were visualized using antibodies against BIII tubulin (green) and Tom20 (red),
respectively, and the nuclei stained with DAPI (blue).
(B) A schematic diagram illustrates the effect of Dia and BSO on the glutathione redox pathway.
(C) High-magnification and contrast images show the change in mitochondrial morphology post-treatment.
(D) A significant decrease in the number of Tom20-positive puncta was observed in axons following both Dia and BSO treatments.
(E) The size of MFN2-positive puncta was also increased in axons following Dia and BSO treatments, as indicated by the arrows.
(legend continued on next page)
Neuron 103, 52–65, July 3, 2019 59
ratios cause both a reduction in GSH conversion to oxoproline
and synthesis of GSH as the result of lower glycine and cysteine
levels (Figure 6L). We conclude that GST loss causes long-term
changes in key metabolites of the GSH pathway, which can
serve to ensure sustained hyperfusion through maintenance of
the GSH:GSSG ratio imbalance.
Gfzf Requires the Coordinated Action of the Thiol-
Specific Peroxidase Jafrac1 and the Thioredoxin
Reductase 1 TrxR-1
To further define howGSTs function tomodulate the GSH:GSSG
ratio and increase mitochondrial fusion in axons in vivo, we con-
ducted targeted epistasis experiments, investigating key com-
ponents of GSH synthesis and degradation pathway (Figure 7).
In Drosophila, a typical NADPH-dependent GR is absent, and
the observed GSH reduction is supported by the Trx-dependent
GR TrxR-1 (Kanzok et al., 2001). Two alternatively spliced tran-
scripts are transcribed from the trxr-1 gene, which separately
target either the mitochondria or the cytoplasm (Missirlis et al.,
2002). Neuronal specific expression of either TrxR-1-cyto or
TrxR-1-mito caused a reduction in excessive mitochondrial
length and rescued the phenotype in gfzf/ clones (Figures 7A
and 7B). This is consistent with the notion that the long mito-
chondrial phenotype is a direct consequence GSSG-induced
Marf oligomerization in the cytoplasm and that either cyto-
plasmic or mitochondrial TrxR-1 can suppress gfzf/ mutant
phenotypes. Increasing levels of GstS1 in gfzf/ mutants also
rescued mitochondrial hyperfusion (Figures 7A–7C), likely by re-
balancing GSH:GSSG ratios.
We next wanted to determine whether decreasing GSH oxida-
tion through decreasing GPx activity was sufficient to impact
mitochondrial size or modify gfzf/mutant phenotypes. Jafrac1
is a major cytosolic peroxiredoxin and is the homolog of the
mammalian PRX2 gene (Orr et al., 2013). Silencing Jafrac1 had
no effect on mitochondria in control neuron clones, but it caused
a complete rescue of mitochondrial phenotypes in a gfzfmutant
background (Figures 7A–7C). These data support the notion that
the decreased GSH levels that likely occur after GST deletion
result from active conversion to GSSG in the cytoplasm via enzy-
matic oxidation. Finally, we also wanted to establish whether we
could induce mitochondrial fusion by simply inhibiting the con-
version of GSSG to GSH by eliminating the GR TrxR-1. Indeed,
RNAi-mediated knockdown of trxr-1 was sufficient to drive
mitochondrial fusion in control neurons, phenocopying gfzf/
mutants, but it had no additive effect in gfzf/ mutant clones
(Figures 7A–7C). These data are consistent with TrxR-1 and
Gfzf acting in the same genetic pathway to modulate mitochon-
drial size.
Taken together, these results argue for a critical in vivo role for
GSH:GSSG ratios in regulating mitochondrial morphology. Once
GSSG levels are sufficiently high relative to GSH to induce
excessive mitochondrial fusion in gfzf/ mutants, hyperfusion
can be inhibited to normal levels again by increasing GSH syn-
thesis or decreasing GSH oxidation. These data further indicate
that inhibiting the enzymatic reduction of GSSG alone is suffi-
cient to drive mitochondrial fusion in vivo.
DISCUSSION
The physiological role of mitochondrial remodeling remains
underexplored, and the function of dynamic mitochondrial
changes in neurons, specifically in neuronal sub-compartments,
is even less understood (Eisner et al., 2018). We show that the
GSH redox pathway controls themitochondrial network in axons
and have identified several molecules whose manipulation alters
the size and shape of mitochondria in vivo. Specifically, we show
that GSTs, known for their cellular detoxification roles in times of
stress, also control the shape of the mitochondrial network, via
fusion inhibition, under normal physiological conditions. Loss
of a single GST-containing gene, gfzf, results in mitochondrial
fusion in vivo through a GSSG-Marf interaction, impacting mito-
chondrial trafficking and neuronal response. This new role of
GSTs provides a potential molecular explanation for how small
molecules that change redox state can alter mitochondrial
morphology in vitro (Shutt et al., 2012) throughMFN oligomeriza-
tion (Mattie et al., 2018).
We find that fission-fusion balance is maintained in adult
post-mitotic neurons in vivo through the coordinated action
of several components in the GSH redox pathway. Gfzf,
TrxR-1, Jafrac1, and GstS1 (Figure 7Di), likely homologs of
GSTT1, TXNRD2, PRX2, and GSTS1 in humans, respectively,
tightly control GSH:GSSG ratios. Ablation of gfzf causes
increased levels of GSSG through the conversion of GSH by
Jafrac1 to promote fusion (Figure 7Dii). Excessive mitochon-
drial fusion can be rescued through overexpression of TrxR-
1 and hence GSSG-GSH conversion (Figure 7D iii), which likely
reduces levels of oxidized Marf. We propose that GST-con-
taining proteins function upstream of Marf and Opa1 in the
mitochondrial fusion pathway, as negative regulators, and
that GSTs are key regulators of mitochondrial length in neu-
rons in vivo (Figure 7E).
Although GSTs are considered the major ROS scavenging
enzymes, we found that a knockout of a single GST gene
in vivo or by modulating GSH:GSSG ratios in vitro using low
doses of small molecules did not induce a detectable level
of ROS. This suggests that small fluctuations in the GSH redox
balance in favor of too much GSSG modulate mitochondrial
dynamics with no overt adverse effects on mitochondrial
function. Prolonged or larger increases of GSSG and/or de-
creases in GSH may increase effects of ROS and ultimately
induce neurotoxicity. This highlights the sensitivity of axonal
mitochondria to the fine balance between mitochondrial hy-
perfusion and cell death when the GSH redox pathway is
dysregulated.
(F) Biochemical analysis showed that levels of MFN1, OPA1, and DRP1 did not change compared to GAPDH following treatments but caused a specific increase
in levels of MFN2 oligomers.
(G) Oligomeric forms were significantly increased more than 10-fold following Dia treatment.
Data were analyzed by 1-way ANOVA and significant differences annotated as *p < 0.05 and **p < 0.01 compared to vehicle treatment. Data in graphs are
expressed as mean ± SEM and n = 3–6 for each group. Scale bars, 50 mm.
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Figure 6. The Effect of Pharmacologically Induced Glutathione Imbalance on Mitochondrial Function and Metabolomic Profiles
(A) Levels of reactive oxygen species (ROS) and mitochondrial membrane potential, determined by MitoSOX and TMRE, respectively, remained unchanged
following Dia and BSO treatments for 2 and 48 h, respectively, but were significantly increased following treatment with FCCP (used as a positive control). Using a
thiol-reactive dye, it could be observed that free thiols within neurons were reduced following both Dia and BSO treatments.
(legend continued on next page)
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Our data show that cytoplasmically localized GSTs in the
Omega and Theta classes can alter mitochondrial dynamics
in vivo, and roles for GSTs are likely more complex and wide-
reaching than previously thought. The presence of aGST domain
within the Charcot-Marie-Tooth-linked gene GDAP1, perhaps
acting in a similar way, may help explain previous results that
show mitochondrial hyperfusion following knockdown (Lo´pez
Del Amo et al., 2015). This suggests that both classical GSTs
and other GST-containing proteins may function cooperatively
to modulate mitochondrial length.
Genome-wide association studies (GWAS) show that poly-
morphisms in GST genes (Allen et al., 2012) are associated
with increased risk in developing Alzheimer’s disease (AD)
and Parkinson’s disease (PD) later in life. Even in sporadic
cases, redox state is significantly altered compared to age-
matched controls (Chinta and Andersen, 2008; Saharan and
Mandal, 2014; Sian et al., 1994; Smeyne and Smeyne, 2013).
Polymorphismsmay increase neuronal susceptibility during ag-
ing through both the accumulation of GSSG resulting in the sub-
sequent oxidation of proteins and the long-term shortage of
GSH needed to remove ROS. Consistent with this notion is
the fact that expression of GSTs is upregulated in situations
of heightened ROS in other cell types, including the closest
homolog of gfzf, GSTT1 (Ito et al., 2011; Raza et al., 2002). It
would be interesting to determine in future experiments whether
there is an additive effect of oxidative stress using toxins in gfzf
mutants that would make neurons more susceptible to
degeneration.
GSSG-induced Marf oligomerization was sufficient to cause
a complete fusion of mitochondria rather than solely the joining
of mitochondria in axons to prime for their fusion later, since
knocking down the inner mitochondrial membrane fusion pro-
tein Opa1 also resulted in a complete rescue of mitochondrial
length. This indicates that outer mitochondrial membrane
fusion is sufficient to trigger inner membrane fusion. Outer
and inner mitochondrial fusion was previously found to be
interdependent, since OPA1 cannot promote fusion in the
absence of MFN (Cipolat et al., 2004). Fission-fusion dynamics
have also been linked to deficits in mitochondrial transport
(Chapman et al., 2013; De Vos et al., 2005; Niescier et al.,
2016), with recent data showing that ROS levels can control
mitochondrial motility through p38 and Miro and Trak (Debat-
tisti et al., 2017). We find that GSSG-induced MFN-2 oligomer-
ization caused significant mitochondrial trafficking problems.
Therefore, movement deficits induced by a redox state change
could be perturbed by two independent pathways occurring
simultaneously.
In summary, we have demonstrated that GSTs are novel
components of the mitochondrial fusion inhibition machinery
in vivo. Our work provides a new link for a cellular pathway
that is intimately involved with cellular responses to metabolic
stress, and our study supports the notion that there are key dif-
ferences in how different compartments of the neuron (i.e., cell
body versus axon) regulate mitochondrial size in vivo in
response to cellular metabolic changes. Future studies that
explore the contributions of GST activity and changes in
GSH:GSSG ratios in neurodegenerative disorders may provide
important new mechanistic insights into how metabolic stress
and changes in mitochondrial dynamics drive axonal loss in
disease.
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(B and C) Quantification showed no effect of low dose Dia and BSO administration on ROS levels or mitochondrial membrane potential, as measured by
fluorescence intensity of MitoSOX and TMRE.
(D) Dia and BSO treatments caused a significant reduction in free thiol levels compared to vehicle treatment, asmeasured by fluorescence intensity and showed a
marginal reduction following FCCP exposure.
(E) Biochemical analysis of GSH andGSSG revealed a reduction of GSH following Dia and BSO administration. Dia treatment also caused a significant increase in
GSSG levels.
(F) Levels of the NADPH were also significantly decreased following both BSO and Dia treatments; however, this was not accompanied changes in NADP.
(G) ATP/ADP ratios were also significantly reduced by the treatments.
(H) Dia and BSO did not causes changes in mtDNA content.
(I) Pathway analysis revealed that changes in the GSH pathway were the most enriched.
(J) BSO treatment caused a significant decrease in the levels of glycine, cysteine-glycine, oxoproline, and glutamine and a significant increase in glutamate
compared to vehicle (indicated by the dashed line).
(K) Dia treatment caused a significant reduction of glycine, cysteine-glycine, glutamine, and glutamine.
(L) Metabolomic changes were mapped onto to the KEGGGSH pathway and show that once GSH levels are reduced, either by blocking GSH synthesis (BSO) or
by oxidizing GSH to GSSG (Dia), the balance cannot be recovered because of the lack of metabolic feedback.
Data for immunofluorescence and mtDNA experiments were analyzed by 1-way ANOVA and significant differences annotated as *p < 0.05 and **p < 0.01
compared to vehicle. Data for GSH-GSSG and NADP-NADPH content were analyzed by 2-way ANOVA and significant differences annotated as *p < 0.05 and
***p < 0.001 compared to vehicle and GSSG as xxp < 0.01 compared to vehicle. Data for metabolite changes are expressed as fold change relative to vehicle,
analyzed by 1-way ANOVA and annotated as *p < 0.05 compared to vehicle. Data in graphs are expressed as mean ± SEM and n = 4–6 for each group. Scale
bar, 100 mm.
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Figure 7. Gfzf Acts Synergistically with Jafrac1 and Trx1 for Fission-Fusion Balance
(A) Targeted epistasis experiments show that long mitochondrial phenotypes caused by gfzf ablation in neuronal clones can be rescued by the pan-neuron
expression of a reductase using 5xUAS-TrxR1-cyto or knockdown of a specific oxidase using 5xUAS-Jafrac RNAi. Mitochondria length in control neurons is
enhanced by expression of 5xUAS-Jafrac1RNAi.
(B) Quantification shows that mitochondrial length was significantly reduced by 5xUAS-TrxR1-cyto, 5xUAS-TrxR1-mito, 5xUAS-GSTS1, and 5xUAS-Jafrac1RNAi,
and mitochondrial length increased in control neurons by expression of 5xUAS-TrxR1RNAi.
(C) Mitochondrial number in gfzf mutant neuronal clones was significantly increased by 5xUAS-TrxR1-cyto, 5xUAS-TrxR1-mito, 5xUAS-GstS1, and 5xUAS-
Jafrac1RNAi expression, and mitochondrial number increased in control neurons by expression of 5xUAS-TrxR RNAi.
(D) A schematic diagram models how these molecules control normal glutathione homeostasis as depicted by reduced GSH/oxidized GSSG ratios (i). GST
ablation was found to alter this balance in favor of increased mitochondrial fusion (ii); however, reducing levels GSSG by increasing levels of TrxR1 restores this
imbalance (iii).
(E) A model of howmitochondrial fusion can be induced based by ablation of GST and subsequent changes in glutathione metabolism. Following GST knockout,
GSH is increased and rapidly (1) converted to GSSG by glutathione peroxidase (2). Metabolic changes cannot compensate of GSH depletion and the imbalance
persists (3). GSSG accumulates (4) and causes the oligomerization of Marf in the axon (5) to induce the fusion of the inner and outer mitochondrial membranes (6).
Data were analyzed by 2-way ANOVA and significant differences annotated as *p < 0.05 and **p < 0.01 between genotypes of the same treatment and xp < 0.05
compared to genotype-matched baseline. Data in graphs are expressed as mean ± SEM and NR 10 wings for each group. Scale bar, 10mm.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
anti-beta III Tubulin Abcam Cat#ab107216; RRID: AB_10899689
anti-MFN2 Abcam Cat#ab56889; RRID: AB_2142629
anti-Tom-20 ProteinTech Cat#11802-1-AP; RRID: AB_2207530
488 goat anti-chicken ThermoFisher Cat#A32931; RRID: AB_2762843
Cy5 Goat anti-rabbit Jackson ImmunoResearch Cat#111-175-144; RRID: AB_2338013
Cy5 Goat anti-mouse Jackson ImmunoResearch Cat#115-175-146; RRID: AB_2338713
anti-Drp1 Abcam Cat#ab56788; RRID: AB_941306
anti-Mitofusin 1 Abcam Cat#ab57602; RRID: AB_2142624
anti-Mitofusin 2 Abcam Cat#ab56889; RRID: AB_2142629
anti-Opa1 Abcam Cat#ab42364; RRID: AB_944549
anti-GAPDH Abcam Cat#ab9485; RRID: AB_307275
HRP Goat anti-mouse Abcam Cat#ab6789; RRID: AB_955439
HRP Goat anti-rabbit Abcam Cat#ab6721; RRID: AB_955447
Chemicals, Peptides, and Recombinant Proteins
Halocarbon Oil 27 Sigma Cat#H8773
Ethyl methane sulfonate (EMS) Sigma Cat#M0880
Vectashield Vector Laboratories Cat#H1000
Trypsin-EDTA ThermoFisher Cat#25300054
DNase Stem Cell Technologies Cat#07900
MEM with L-glutamine ThermoFisher Cat#11095-080
Horse serum ThermoFisher Cat#26050070
Fetal Bovine Serum Sigma Cat#F9665
Neurobasal media ThermoFisher Cat#21103049
B-27 ThermoFisher Cat#17504044
GlutaMax ThermoFisher Cat#35050061
Paraformaldehyde EMS Cat#15710
Dapi ThermoFisher Cat#D1306
SYBR PCR Premix Takara Bio Cat#639676
Critical Commercial Assays
Glutathione Assay Kit Cayman Chemical Cat#703002
NADP/ NADPH colorimetric Kit Abcam Cat#ab186033
Bioluminescent ADP/ATP Ratio Assay Kit Abcam Cat#ab65313
MitoSOX Red ThermoFisher Cat#M36008
TMRE Abcam Cat#ab113852
Thiol-Tracker ThermoFisher Cat#T10095
Experimental Models: Cell Lines
Primary embryonic neurons derived from time
mated C57BL/6 mice
Charles River https://www.criver.com/products-
services/find-model/c57bl6-
mouse?region=3671
Experimental Models: Organisms/Strains
OK371-Gal4 BDSC RRID: BDSC_26160
GMR-myr::GFP BDSC RRID: BDSC_7112
Tubulin-Gal4 BDSC RRID: BDSC_5138
Elav-Gal4c155 BDSC RRID: BDSC_458
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
n-Synaptobrevin-Gal4 BDSC RRID: BDSC_51635
Nrv2-Gal4 BDSC RRID: BDSC_6800
Cha-Gal4 BDSC RRID: BDSC_6798
29A07-Gal4 Rubin Lab (Manning et al., 2012) N/A
10xUAS-IVS-myr::tdTomato BDSC RRID: BDSC_32222
5xUAS-mito::GFP BDSC RRID: BDSC_8442
FRT2A BDSC RRID: BDSC_1997
FRT82B BDSC RRID: BDSC_2035
tub-Gal80 BDSC RRID: BDSC_5135
ey-FLP BDSC RRID: BDSC_5577
asense-FLP2c Freeman Lab (Neukomm et al., 2014) N/A
asense-FLP2e Freeman Lab (Neukomm et al., 2014) N/A
asense-FLP3b Freeman Lab (Neukomm et al., 2014) N/A
5xUAS-mito::tdTomato Freeman Lab (This paper) N/A
5xUAS-mCD8::GFP BDSC RRID: BDSC_32192
5xUAS-redStinger (NLS::Cherry) BDSC RRID: BDSC_8546
5xUAS-Drp1 Feany Lab (DuBoff et al., 2012) N/A
5xUAS-TrxR1-mito Jackle Lab (Missirlis et al., 2002) N/A
5xUAS-TrxR1-cyto Jackle Lab (Missirlis et al., 2002) N/A
5xUAS-GstS1 Pallanck Lab (Whitworth et al., 2005) N/A
5xUAS-lamp1::GFP BDSC RRID: BDSC_42714
5xUAS-Rab11::GFP BDSC RRID: BDSC_8506
5xUAS-SKL::GFP BDSC RRID: BDSC_28880
20xUAS-mito::GCaMP5 Freeman Lab (This paper) N/A
20xUAS-GCaMP5 Freeman Lab (This paper) N/A
5xUAS-roGFP2-Orp1 BDSC RRID: BDSC_67666
5xUAS-Grx1-roGFP2 BDSC RRID: BDSC_67662
UAS-mito-roGFP2-Orp1 BDSC RRID: BDSC_67667
UAS-mito-Grx1-roGFP2 BDSC RRID: BDSC_67664
5xUAS-MitoTimer BDSC RRID: BDSC_57323
5xUAS-Drp1RNAi BDSC RRID: BDSC_51483
5xUAS-Opa1RNAi VDRC RRID: VDRCID_330266
5xUAS-MarfRNAi BDSC RRID: BDSC_55189
5xUAS-MarfRNAi VDRC RRID: VDRCID_105261
5xUAS-Jafrac1RNAi VDRC RRID: VDRCID_330046
Milton [EY4443] BDSC RRID: BDSC_19628
Drp11 BDSC RRID: BDSC_24885
Drp12 BDSC RRID: BDSC_24899
Marf [J] BDSC RRID: BDSC_57096
Opa1 [s3475] BDSC RRID: BDSC_12188
Pink1[5] BDSC RRID: BDSC_51649
Mi(MIC)gfzfMI08697 BDSC RRID: BDSC_51102
gfzfCZ811 BDSC RRID: BDSC_9436
gfzfCU338 BDSC RRID: BDSC_9438
gfzfDC806 BDSC RRID: BDSC_9439
gfzfCL1027 BDSC RRID: BDSC_9437
5xUAS-gfzfRNAi BDSC RRID: VDRCID_25747
5xUAS-gfzfRNAi BDSC RRID: VDRCID_33932
(Continued on next page)
Neuron 103, 52–65.e1–e6, July 3, 2019 e2
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Gaynor
Smith (Smithga@cardiff.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Drosophila Strains
All Drosophila strains (commercially available and generated) used are detailed in the Key Resources Table. The age and number
used for each experiment are detailed in the figure legends.Drosophila strains used formutagenesis and to generateMARCMclones:
OK371-Gal4, 10xUAS-IVS-myr::tdTomato, 5xUAS-mito::GFP, asense-FLP2c; FRT82B, tub-Gal80 (females) and OK371-Gal4,
10xUAS-IVS-myr::tdTomato; FRT2A, FRT82B (males). ey-FLP; FRT82B, GMR-myr::GFP was used for ERG experiments. The
following Drosophila strains used for general experimental procedures and epistasis experiments: n-Synaptobrevin-Gal4, OK371-
Gal4, Nrv2-Gal4, Cha-Gal4, R29A07-Gal4 (Rubin lab fly light collection), FRT19A, FRT40A, FRT82B, asense-FLP2c, asense-
FLP2e, asense-FLP3b, tub-Gal80, 10xUAS-IVS-myr::tdTomato, 5xUAS-mito::tdTomato, 5xUAS-mCD8::GFP, 5xUAS-mito::GFP,
5xUAS-redStinger (NLS::Cherry), 5xUAS-Drp1 (a gift from the Feany Lab (DuBoff et al., 2012)), 5xUAS-TrxR1-mito & 5xUAS-
TrxR1-cyto (a gift from the Langa and Jackle Labs (Missirlis et al., 2002)), 5xUAS-GstS1 (a gift from the Pallanck Lab (Whitworth
et al., 2005)), 5xUAS-GstO1 (a gift from the Yim Lab (Kim et al., 2012), 5xUAS-lamp1::GFP, 5xUAS-Rab11::GFP, 5xUAS-SKL::GFP,
20xUAS-mito::GCaMP5, 20xUAS-GCaMP5, 5xUAS-roGFP-Orp1, 5xUAS-roGFP-Grx, UAS-mito-roGFP2-Orp1, UAS-mito-roGFP2-
Grx and 5xUAS-MitoTimer. The following commercially available RNAi lines andmutants were used for further epistasis experiments
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
5xUAS-dGstO1 Yim lab (Kim et al., 2012) N/A
5xUAS-hGSTO1-HA Bellen lab (This paper) N/A
5xUAS-hGSTO2-HA Bellen lab (This paper) N/A
5xUAS-hGSTT1-HA Bellen lab (This paper) N/A
5xUAS-hGSTT2-HA Bellen lab (This paper) N/A
5xUAS-hGSTM1-HA Bellen lab (This paper) N/A
5xUAS-gfzf Freeman lab (This paper) N/A
5xUAS-gfzf(DN) Freeman lab (This paper) N/A
5xUAS-gfzf::GFP Freeman lab (This paper) N/A
BACCH322-97B15 (genomic gfzf, landing site
VK00037)
Freeman lab (This paper) N/A
autosome deficiencies BDSC https://bdsc.indiana.edu/stocks/df/
dfkit-info.htm
Oligonucleotides
mtDNA primer 50-CCC AAG CAT ATA AGC TAG
TAC-30
IDT N/A
mtDNA primer 50-ATA TAAGTC ATA TTT TGGGAA
CTA C-30
IDT N/A
nDNA primer 50-CGTGGGCTCCAGCAT TCT A-30 IDT N/A
nDNA primer 50-TCA CCA GTC ATT TCT GCC TTT
G-30
IDT N/A
Software and Algorithms
Zen Blue Ziess https://www.zeiss.com
Zen Black Ziess https://www.zeiss.com
Prism7 Graph Pad https://www.graphpad.com
ImageJ Version 2.0 https://www.imagej.nih.gov
Slidebook 6 3i https://www.intelligent-imaging.com/
slidebook
MetaboAnalyst Version 3.5 https://www.metaboanalyst.ca
ChromaTOF Version 2.32 https://www.leco.com
Other
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and as positive controls for the mutagenesis screen: 5xUAS-Drp1RNAi (51483), 5xUAS-Opa1RNAi (330266), 5xUAS-MarfRNAi (55189),
5xUAS-MarfRNAi (105261), 5xUAS-Jafrac1RNAi (330046), Milton [EY4443], Drp11, Drp12, Marf [J], Opa1 [s3475] and Pink1[5]. Other
commercially available gfzf alleles, deficiency lines spanning the region and RNAi lines tested were: Mi(MIC)gfzfMI08697, gfzfCZ811,
gfzfCU338, gfzfDC806, gfzfCL1027, Df BSC221, 5xUAS-gfzfRNAi (25747) and 5xUAS-gfzfRNAi (33931).
A mixture of male and female flies were used throughout. No sex specific differences were observed. The majority of experiments
were conducted at 7 days post eclosion (p.e.) with time course experiments done at 1, 7 and 28 days p.e. Flies which showed clear
physical damage to the wings were not selected.
Generation of Drosophila lines
The plasmids listed below were generated by standard sub-cloning procedures, using a 5xUAS, w+ marker backbone and injected
into embryos using Phi31 integration by BestGene: 5xUAS-gfzf, 5xUAS-gfzf(DN), 5xUAS-gfzf::GFP. Drosophila harboring the
BACCH322-97B15 were made through recombineering by BestGene. Gateway cloning was used to generate the following human
cDNA constructs in pUASg-HA.attB (Bischof et al., 2013), used for rescue experiments: UAS-hGSTO1-HA, UAS-hGSTO2-HA,
UAS-hGSTT1-HA, UAS-hGSTT2-HA and UAS-hGSTM1-HA (human constructs and transgenic stocks made in the Bellen Lab at
Baylor College of Medicine).
Primary Culture
Cortical neuronal cultures were prepared from dissected embryos at E15, using wild-type naive time pregnant mice of the C57BL/6
strain (Charles River) and left to mature for 2 weeks before experiments conducted. Time pregnant mice were housed overnight in
standard conditions and anaesthetized using isoflurane. Procedureswere carried out according to the Institutional Animal CareCom-
mittee at the Vollum Institute (Oregon Health and Sciences University). A mixture of male and female embryos were used. Whole
cortices were removed in HBSS-HEPES buffer, washed 10x and incubated in Trypsin/DNase for 5 mins at 37C. Tissue was washed
3x beforemechanical dissociation using standard pipetting procedure. Cells were centrifuged at 800rpm for 5mins and resuspended
into a single cell solution in MEM with L-glutamine, 10% Horse serum and 10% Fetal Bovine Serum to a density of 0.5 3 106. Cells
were plated onto Poly-L-lysine coated coverslips or plates and incubated at 37C for 24 h. Media was then replaced with Neurobasal
media containing B-27 and Glutamax, replenished every 2-3 days for 2 weeks.
METHOD DETAILS
Mutagenesis Screen for mitochondrial modifying phenotypes
Axonal MARCM clones were induced according to (Neukomm et al., 2014), and residing mitochondria were visualized in the L1 vein
of each wing usingUAS-mito::GFP. Any F1male flies that displayedmitochondrial phenotypes were saved, bred, and outcrossed, as
defined in (Neukommet al., 2017).Drosophila stockswere kept on standard cornmeal and agar supplementedwith dry yeast at 25C.
The mutagenesis screen was carried out using males that were starved for 8 h before consuming mutagen for a further 12 h (25mM
ethyl methane sulphonate (EMS) in 1% sucrose). Males were recovered in fresh vials for 12 hours before breeding. The right wings
of anesthetized F1 flies, aged 7 days at 25C, were cut as close to the body as possible, using dissection Scissors (EMS, VANNAS).
20-30 wings were then mounted in Halocarbon Oil 27 (Sigma) on a microscopy slide, a coverslip placed on top, and then used
immediately for microscopy. Flies were returned to vials in a numerical order relative to order of the wings.
In vivo live cell imaging
Live cell imaging was carried out according to a modified protocol by (Vagnoni and Bullock, 2016). Following CO2 anesthesia, the
head, thorax and legs of the fly were additionally restrained by low melt agarose (Sigma), which was poured into a 5 mm indentation
hollowed from a glass slide. A glass coverslip was placed directly on top of the wings held perpendicular to the body by Halocarbon
Oil 27 (Sigma) and used immediately for imaging. 10-minute interval videos were used for each fly and image acquisition was carried
out every 2 s. 4 animals were used per group and videos analyzed in a blind randomized fashion.
Electrophysiology
ERGs from flies were recorded as described previously (Fabian-Fine et al., 2003) and (Bayat et al., 2012), with Ag/AgCl wire
electrodes sheathed with glass micropipettes containing Beadle-Ephrussi ringer. A fluorescence excitation light source (CoolLed
pE-2 fitted with a 470 nm LED attenuated through a neutral density filter) was used to provide 1 s pulses of light. LED output was
regulated to provide different stimulus intensities, with 50% output corresponding approximately to 0.2 mW/cm2 as converted
from illuminance measurements using a light meter (Model 230, CHY-Firemate, Taiwan). Flies were allowed to adapt for 5 min to
ambient light (3 lux) before experiments. 6 animals were used per group and groups were blind to blind to the investigator. Signals
were digitized at a 1 kHz rate and analysis of the response variables was automated using a custom script in Igor Pro.
Immunocytochemistry
Primary neuronal culture medium was removed from cells adhered to coverslips and were washed with PBS (with Ca2+ and Mg2+
and fixed using 4%PFA at room temperature for 15min. Neuronswerewashed 3x in PBS, permeabilized in PTX for 5min andwashed
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3x in PBS. Cells were incubated in 5% horse serum in PBS for 60mins and incubated in the blocking solution with the following pri-
mary antibodies at 4C overnight: Chicken anti-beta III Tubulin (ab107216) was used at a concentration of 1:1000, mouse anti-MFN2
(ab56889) used at 1:500 and rabbit anti Tom-20 (11802-1-AP) used at 1:250. Primary neurons were washed 5x in PBS and further
incubated for 2 h at room temperature with: 488 goat anti-chicken (Jackson lab) and Cy5 Goat anti-rabbit/ anti-mouse (Jackson
lab). Coverslips were washed 3x PBS, stained with Dapi (Fisher), washed 5x PBS and mounted in Vectashield. Experiments were
repeated 6 times, each run in triplicate and 3 images averaged per well and mitochondria analyzed in a blind automated fashion.
Biochemistry
Western Blot analysis was performed on neuronal cell lysates following pharmacological treatments with BSO and Diamide. Protein
levels were normalized using a Bradford assay and resolved by SDS–PAGE, transferred to polyvinylidene difluoride membrane and
probed with the following antibodies: Drp1 (Abcam ab56788), Mitofusin 1 (Abcam ab57602), Mitofusin 2 (Abcam ab56889), Opa1
(Abcam ab42364) and GAPDH (Abcam ab9485). Bands were visualized using Hrp conjugated antibodies (Abcam). 3 samples
were used per group and experiments were run in triplicate.
Drug treatments
Two week old primary cultures were treated with either diamide (Dia) at a concentration of 100mm for 2hours or L-Buthionine-sulfox-
imine (BSO) at a concentration of 600mm for 48hours, following an initial dose response curve to determine a dose that does not cause
toxicity. Drugs were dissolved in DMSO
GST KO cell generation
One week old primary cultures were transfected with gRNA/Cas9 Knockout (KO) plasmids using sequences targeting mouse GSTT1
(SC-420721) or were scrambled (SC-418922), using GeneJuice (70967 Merck) according to the manufacturer’s instructions. Cells
were left in culture for 1 week and selected by the GFP marker for further analysis. Experiments were repeated 4 times, each run
in triplicate and 3 cells analyzed per well.
Analysis of mtDNA content
mtDNA was quantified using real-time (RT) qPCR, performed according to (Fuke et al., 2011), using SYBR Premix Ex Taq reagent
(Takara Bio, Otsu, Japan) according to the manufacturer’s instructions. For estimation of amounts of mtDNA in mouse primary
cortical neurons, mtDNA was amplified using the primer pair (50-CCC AAG CAT ATA AGC TAG TAC-30) and (50-ATA TAA GTC
ATA TTT TGG GAA CTA C-30), used in the following qRT-PCR protocol: 95C for 20 s, 55C for 20 s, 72C for 80 s (30 cycles). To
quantify nDNA, the apoB gene was used for reference. Amplification was carried out using the following primer pair (50-CGT GGG
CTC CAG CAT TCT A-30) and (50-TCA CCA GTC ATT TCT GCC TTT G-30) using the following protocol: 40 cycles of two-step PCR
prior to: 95C for 1 min, 95C for 10 s and 60C for 30 s. These real-time qPCRs were carried out in quadruplicate.
GSH/ GSSG, NADP/ NADPH & ATP/ADP biochemical analysis
For GSH/GSSG quantification primary cortical neurons were washed in PBS, dissociated and pelleted by centrifugation. Cells were
then homogenized, the supernatant extracted, deprotienated and used immediately in a 96 well assay format. Quantitative detection
of GSH and GSSG was carried out using a Glutathione Assay Kit (Cayman Chemical) according to the manufacturer’s instructions.
Standards and experimental samples were run in duplicate on a microplate reader (SpectraMax) set to measure absorbance at
405nM. For detection of NADP/NADPH primary neuronal cultures were extracted and prepared by buffers provided by the NADP/
NADPH colorimetric Kit (Abcam). Detection was measured, 2 h after final incubation step, using the microplate reader set at
450nM. ATP/ADP ratios were analyzed using the Bioluminescent ADP/ATP Ratio Assay Kit (ab65313) according to the manufac-
turer’s instructions. Cell lysate samples were also run in triplicate and experiments repeated 4-6 times.
LDH release assay for cell death
Neurons were seeded in 96 well plates and were left to mature for 2 weeks Following appropriate drug treatments cell death was
analyzed according to (Smith et al., 2016), using an LDH release assay kit (Cayman Chemical). N = 3 per group. Controls and exper-
imental wells were run in triplicate.
Live fluorescent dyes
For live cell imaging experiments primary neuronswere adhered directly to the bottom of Poly-L-Lysine coated 12-well plates. For the
analysis of mitochondrial derived mitochondrial derived reactive oxygen species (ROS), mitochondrial membrane potential and free
thiols in live primary neuronal mouse cortical cultures following drug treatments, MitoSOX (Fisher), TMRE (Abcam) and Thiol-Tracker
(Fisher). Live fluorescent probes were used according to the manufacturer’s instructions, including doses and times stated. Opti-
mized methods for this experiment: TMRE - 100nM for 20mins incubation. Experiments were repeated 4-6 times and each sample
run in triplicate. 3 images were taken per well and averaged. Images were analyzed in an investigator blind fashion.
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Whole-Genome Sequencing
Gene mutations responsible for mitochondrial phenotypes were discovered through the application of next generation sequencing.
gDNA was extracted from 200 heterozygous male mutant adult flies and directly sequenced on a HiSeq2000 next-generation
sequencing platform (Illumina). Bioinformatics analysis for read alignment and variant investigation was carried out through at the
University of Miami Miller School of Medicine, Center for Genome Technology.
QUANTIFICATION AND STATISTICAL ANALYSIS
Microscopy
For the visualization of mitochondrial and axons, in unfixed wings or fixed brains were imaged on a 3I spinning disc confocal micro-
scope or on a Zeiss LSM 880 microscope. Data acquisition was carried out using Slidebook 6 or Zen Blue and Zen black software
packages.
Metabolomics
Metabolomic analysis was carried out at the University of California Davis Metabolomics Core, using a Leco Pegasus IV mass spec-
trometer. ChromaTOF v2.32 was used for data preprocessing. Methodological details to be found in (Fiehn et al.). MetaboAnalyst
v3.5 was used for statistical and pathway enrichment analysis and changes referenced to the KEGG pathway: glutathione meta-
bolism - Mus musculus (mouse).
Analysis
Image processing was carried out with either Slidebook 6, Zen blue or Zen black and ImageJ 2.0 used for quantification of: mitochon-
drial length, mitochondrial number, fluorescence intensity and counting of puncta. All statistical tests were carried out using Prism 7
unless otherwise stated. Information on statistical tests used for each experiment and number of samples is indicated in the Fig-
ure legends. Statistical methods were chosen to fit data distributions and the number of groups per experiment as determined using
Prism 7. For in vivo experiments where mitochondrial length and number were quantified at least 10 animals were quantified per
group, 1-7 axons quantified for each animal. For in vitro experiments at least 3 separate experiments were performed, each run in
triplicate.
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